Recruiting

Dupilumab

Sponsor:

Northwestern University

Code:

NCT06892704

Conditions

Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)

Smell Loss

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

Dupilumab - Standard Dose

Study Details

Brief summary:

The goal of this observational study is to learn what can predict the return of the sense of smell in patients with chronic rhinosinusitis with nasal polyps being treated with dupilumab. The main questions it aims to answer are:

1. Does obstruction of the olfactory cleft predict return of the sense of smell?
2. Do electrophysiological signals generated by breathing and sniffing behavior predict return of the sense of smell?

Participants starting dupilumab will undergo assessment for their degree of olfactory cleft obstruction, and an electrophysiologic assessment of their olfactory cleft and be followed over 6 months of treatment with dupilumab.

Conditions

Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)

Smell Loss

Study ID

NCT06892704

Start date

May 1, 2025

Status verified date

Jul, 2026

Completion date

Dec 31, 2027

Anticipated

Primary completion date

Apr 30, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

  • Well documented history of CRSwNP
  • BSIT age/sex classified as "abnormal" score
  • Self-reported stable olfactory deficit of moderate to severe quality > 3 months
  • Prior endoscopic sinus surgery >3 months, <10 years prior

Study Design

Enrollment

30 participants

Anticipated

Interventions and Outcome Measures

Arms

Dupilumab Treatment

Patients who had prior endoscopic sinus surgery for CRSwNP with persistent smell loss initiating dupilumab

Interventions

Dupilumab - Standard Dose

24 weeks of dupilumab 300mg q2 weeks

Primary outcome measure

  • Status change of the Brief Smell Identification Test [ Time Frame: 26 weeks ]

Central Contacts and Locations

Central contacts

Clinical Coordinator

312 6958182aditi.agarwal@northwestern.edu

Bruce Tan, MD

312 6958182btan@nm.org

Locations

Northwestern University Feinberg School of Medicine

Recruiting

Chicago, Illinois, United States, 60611

Contacts

Aditi Agarwal, MBBS, MSCI

312 6958182aditi.agarwal@northwestern.edu

Bruce Tan, MD MS

312 6958182btan@nm.org

Principal Investigator:

Bruce Tan, MD, MS

More Information

Sponsor

Northwestern University

Last update posted

Jul 16, 2026

Last verified

Jul, 2026

Keywords

  • Dupilumab
  • Chronic Rhinosinusitis with Nasal Polyps
  • Smell Loss
  • Electrophysiology

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Northwestern University on 2026-07-16.